Company research
BullFrog AI Holdings, Inc.
CIK 1829247Updated Sep 24, 2026
BFRG price & chart
Loading TradingView…
NASDAQ:BFRG on TradingView ↗In the news
BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference ↗
Seeking Alpha
Bullfrog AI Holdings, Inc. (BFRG) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript ↗
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026 ↗
Catalyst Watch: Tech majors report, FOMC, Jersey Mike's IPO and more oil anxiety ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,808,351Source | 5,551,830Source | 2,776,586Source | 80,369Source |
| Property, Plant and Equipment, NetUSD | 2,525Source | 4,250Source | 5,974Source | 7,699Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,183,705Source | 5,435,983Source | 2,624,730Source | — |
| Assets, CurrentUSD | 2,584,156Source | 5,547,580Source | 2,770,612Source | 72,670Source |
| Prepaid Expense and Other Assets, CurrentUSD | 400,451Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 672,022Source | 588,090Source | 184,350Source | 3,137,721Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 1Source | 1Source | 1Source | 1Source |
| Common Stock, Value, IssuedUSD | 114Source | 91Source | 61Source | 40Source |
| Additional Paid in CapitalUSD | 25,427,838Source | 21,757,204Source | 12,347,098Source | 1,341,662Source |
| Retained Earnings (Accumulated Deficit)USD | -23,291,624Source | -16,793,556Source | -9,754,924Source | -4,399,055Source |
| Stockholders' Equity Attributable to ParentUSD | 2,136,329Source | 4,963,740Source | 2,592,236Source | -3,057,352Source |
| Additional Paid in Capital, Common StockUSD | 2,000,000Source | — | — | — |
| Liabilities and EquityUSD | 2,808,351Source | 5,551,830Source | 2,776,586Source | 80,369Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 672,022Source | 588,090Source | 184,350Source | 3,137,721Source |
| Accounts Payable, CurrentUSD | 168,151Source | 435,934Source | 103,656Source | 543,993Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 503,871Source | 152,156Source | 80,694Source | 416,072Source |
| Deferred Revenue, CurrentUSD | — | — | — | 32,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,010,631Source | 943,649Source | 631,533Source | 340,152Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -267,783Source | 332,278Source | -440,337Source | 475,399Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,522,265Source | -5,610,249Source | -6,001,299Source | -910,890Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | -8,744Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 8,744Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 2,374,987Source | 8,421,502Source | 8,568,359Source | 967,290Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,147,278Source | 2,811,253Source | 2,567,060Source | 47,656Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,288,705Source | 5,435,983Source | 2,624,730Source | 57,670Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 5,629Source | 18,158Source | 93,916Source | 5,757Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 722,304Source | 940,642Source | — | — |
| DepreciationUSD | 1,725Source | 1,724Source | 1,725Source | 1,045Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -92,959Source | — |
| General and Administrative ExpenseUSD | 4,816,790Source | 5,013,118Source | 3,994,710Source | 1,307,882Source |
| InterestExpenseNonoperatingUSD | 5,629Source | 18,158Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -6,498,068Source | -6,993,647Source | -5,355,869Source | -2,802,487Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -6,498,068Source | -7,038,632Source | — | — |
| Nonoperating Income (Expense)USD | 96,568Source | 242,736Source | 11,655Source | -346,686Source |
| Operating ExpensesUSD | 6,616,528Source | 7,236,383Source | 5,427,324Source | 2,465,001Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 459Source |
| Proceeds from Issuance of Common StockUSD | 2,467,533Source | — | 7,293,651Source | — |
| Stock or Unit Option Plan ExpenseUSD | — | — | 592,268Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 116,670Source | — | 65,000Source | 10,000Source |
| Cost of RevenueUSD | — | — | 5,200Source | 800Source |
| Operating Income (Loss)USD | -6,594,636Source | -7,236,383Source | -5,367,524Source | -2,455,801Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 459Source |
| Net Income (Loss) Attributable to ParentUSD | -6,498,068Source | -6,993,647Source | -5,355,869Source | -2,802,487Source |
| Earnings Per Share, BasicUSD per share | -0.63Source | -0.85Source | -0.89Source | -0.7Source |
| Earnings Per Share, DilutedUSD per share | -0.63Source | -0.85Source | -0.89Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 10,337,073Source | 8,245,353Source | 6,049,819Source | 4,009,852Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 10,337,073Source | 8,245,353Source | 6,049,819Source | — |
| Interest Expense (non-operating)USD | 5,629Source | 18,158Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 4,816,790Source | 5,013,118Source | 3,994,710Source | 1,307,882Source |
| Gross ProfitUSD | 21,892Source | — | 59,800Source | 9,200Source |
| Interest ExpenseUSD | — | — | 79,089Source | 347,145Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -6,498,068Source | -7,038,632Source | — | — |
| Nonoperating Income (Expense)USD | 96,568Source | 242,736Source | 11,655Source | -346,686Source |
| Operating ExpensesUSD | 6,616,528Source | 7,236,383Source | 5,427,324Source | 2,465,001Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | 44,985Source | — | — |
| Research and Development ExpenseUSD | 1,799,738Source | 2,223,265Source | 1,432,614Source | 609,270Source |
Offerings
Registration 333-296363
Filing attachments
ex99-1.htm · 8-K · 2026-04-22
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 BullFrog AI Regains Compliance with Nasdaq Shareholders’ Equity Requirement Strengthened balance sheet provides capital runway into late 2027 GAITHERSBURG, Md., April 22, 2026 - BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced that it has received a written notice…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners First commercial agreement with a top 5 global pharmaceutical company anchors a growing pipeline of enterprise discussions; runway secured into late 2027 GAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) - BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) (“B…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-30
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder Commercial agreement serves as high-profile third party validation of BullFrog AI’s proprietary capabilities Agreement utilizes BullFrog AI’s end-to-end analytical AI platform to accelerate drug discovery and development program GAITHERSBURG, Md., March 30, 2026 - BullFrog AI Holdings, Inc.…
Read attachment ↗